Signature Research Project

签名研究项目

基本信息

项目摘要

JASPR (SIGNATURE PROJECT): ABSTRACT Significance: The significance of this Signature Project is derived from its powerful combination of (1) targeting a high-risk population -- adult patients at risk for suicide presenting to emergency departments (EDs); (2) addressing trenchant barriers that have prevented delivery of suicide-related evidence-based practices (EBPs) in the ED through an innovative, multi-component, NIMH-funded technology called Jaspr; and (3) evaluating Jaspr’s efficacy, effectiveness, and implementation, all in the same highly efficient study. Investigators: Jaspr’s project team has pioneered ED systems-based suicide prevention using continuous quality improvement implementation strategies (Boudreaux, Kiefe, Larkin, Johnson, Volturo); digital behavioral health technology development and deployment (Boudreaux, Dimeff, Gerber); using multi-method approaches, including patient-reported measures, electronic health record (EHR) data, and death registries, for outcome and intervention target ascertainment (Boudreaux, Kiefe, Gerber); implementation science research design and analytic methodologies (Kiefe, Yang, Larkin); and healthcare economics (Singh, Clements). Innovation: This will be the first study to comprehensively evaluate a multi-component suicide prevention technology that facilitates delivery of suicided-related EBPs while replacing wasted waiting time with productive time. Its multi-component nature satisfies several key performance elements for systems adopting Zero Suicide. A novel, award-winning hybrid study design called Complementary Randomized Controlled Trial and Real-World Study for Efficacy, Effectiveness, and Implementation Design (CREID) will be used. Approach: CREID comprises two separate but related components or parts. Part A, Randomized Controlled Trial (RCT), will be a patient-level, randomized, parallel-arm, single-blind trial (n=670) comparing Jaspr (Intervention) to enhanced treatment as usual (ETAU; Active Comparator Control). Consistent with NIMH’s experimental therapeutics paradigm, Part A’s primary aim is to determine Jaspr’s efficacy in improving suicide- related outcomes in the 12 months after the index ED visit and to explore its potential mechanisms of action through engaging patient intervention targets and EBP delivery. In Part B, Real-World Study, four diverse EDs will implement Jaspr as part of routine care. Part B’s primary aim will be to evaluate Jaspr’s effectiveness when used in a real-world setting. Finally, both Parts will be used to explore Jaspr’s implementation, including establishing system, clinician, and patient factors anticipated to affect Jaspr adoption and implementation. Environment: The UMass Chan Medical School (UMass), Jaspr Health, and partnering organizations have proven their ability to support this ambitious study by their success with numerous NIMH-funded, systems-based suicide prevention studies and SBIR/STTRs technology grants, including the SBIR that created Jaspr. Impact: Accelerated translation of Jaspr and advancing knowledge pertaining to the implementation of suicide care technologies in the ED setting has the potential to help thousands of suicidal individuals annually.
Jaspr(签名项目):抽象

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Edwin D Boudreaux其他文献

Edwin D Boudreaux的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Edwin D Boudreaux', 18)}}的其他基金

Administrative Core
行政核心
  • 批准号:
    10577118
  • 财政年份:
    2023
  • 资助金额:
    $ 114.38万
  • 项目类别:
The Center for Accelerating Practices to End Suicide through Technology Translation (CAPES)
通过技术转化加速结束自杀实践中心 (CAPES)
  • 批准号:
    10577117
  • 财政年份:
    2023
  • 资助金额:
    $ 114.38万
  • 项目类别:
CDR Administrative Supplement for COVID-19 Impacted NIMH Research
针对受新冠肺炎 (COVID-19) 影响的 NIMH 研究的 CDR 行政补充
  • 批准号:
    10617502
  • 财政年份:
    2022
  • 资助金额:
    $ 114.38万
  • 项目类别:
Telehealth to Improve Prevention of Suicide (TIPS) in EDs
远程医疗可改善急诊科的自杀预防 (TIPS)
  • 批准号:
    10322028
  • 财政年份:
    2021
  • 资助金额:
    $ 114.38万
  • 项目类别:
Telehealth to Improve Prevention of Suicide (TIPS) in EDs
远程医疗可改善急诊科的自杀预防 (TIPS)
  • 批准号:
    10532210
  • 财政年份:
    2021
  • 资助金额:
    $ 114.38万
  • 项目类别:
Reward-based technology to improve opioid use disorder treatment initiation after an ED visit
基于奖励的技术可改善急诊就诊后阿片类药物使用障碍治疗的启动
  • 批准号:
    10414138
  • 财政年份:
    2019
  • 资助金额:
    $ 114.38万
  • 项目类别:
Computerized Adaptive Suicidal Risk Stratification and Prediction
计算机化自适应自杀风险分层和预测
  • 批准号:
    10254382
  • 财政年份:
    2019
  • 资助金额:
    $ 114.38万
  • 项目类别:
Reward-based technology to improve opioid use disorder treatment initiation after an ED visit
基于奖励的技术可改善急诊就诊后阿片类药物使用障碍治疗的启动
  • 批准号:
    10337501
  • 财政年份:
    2019
  • 资助金额:
    $ 114.38万
  • 项目类别:
Reward-based technology to improve opioid use disorder treatment initiation after an ED visit
基于奖励的技术可改善急诊就诊后阿片类药物使用障碍治疗的启动
  • 批准号:
    10794875
  • 财政年份:
    2019
  • 资助金额:
    $ 114.38万
  • 项目类别:
Deriving a Clinical Decision Rule for Suicide Risk in the Emergency Department Setting
得出急诊科自杀风险的临床决策规则
  • 批准号:
    10299606
  • 财政年份:
    2019
  • 资助金额:
    $ 114.38万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了